@article{c084ae26157d4fd998ab95e5541d743f,
title = "How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia",
abstract = "NA",
keywords = "COVID-19, Chronic lymphocytic leukemia, Rituximab, venetoclax, COVID-19, Chronic lymphocytic leukemia, Rituximab, venetoclax",
author = "Marina Deodato and Frustaci, \{Anna Maria\} and Paolo Sportoletti and Luca Laurenti and Roberta Murru and Andrea Visentin and Gianluigi Reda and Mauro, \{Francesca Romana\} and Giulia Quaresmini and Anna Vanazzi and Candida Vitale and Lorella Orsucci and Massimo Massaia and Alessandro Sanna and Marina Motta and Adalberto Ibatici and Isacco Ferrarini and Chiara Borella and Marzia Varettoni and Monica Tani and Sara Marinoni and Andrea Ferrario and Giulia Zamprogna and Marco Montillo and Alessandra Tedeschi",
year = "2022",
doi = "10.1080/10428194.2022.2053532",
language = "English",
volume = "63",
pages = "1985--1988",
journal = "LEUKEMIA \& LYMPHOMA",
issn = "1042-8194",
publisher = "Taylor \& Francis Limited:Rankine Road, Basingstoke RG24 8PR United Kingdom:011 44 1256 813035, EMAIL:
[email protected],
[email protected], INTERNET: http://www.tandf.co.uk, Fax: 011 44 1256 330245",
}